Literature DB >> 1700828

Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis.

G T Spear1, B L Sullivan, A L Landay, T F Lint.   

Abstract

The ability of complement to inactivate human immunodeficiency virus (HIV) in the presence of specific antibody was evaluated. HIV was treated with complement and/or antibody, and then its titer was determined on the CD4+ H9 cell line. While complement alone had no effect on the HIV titer, complement plus subneutralizing levels of antibody resulted in titer reductions. Complement sources deficient in membrane attack component C5 or C8 did not inactivate antibody-treated HIV, suggesting that neutralization occurred via lysis. This possibility was investigated by assessing release of reverse transcriptase (RT) from the virion. Antibody plus complement, but neither reagent alone, released RT from HIV in a dose-dependent manner. Release of RT did not occur with C5- or C8-deficient sera, also indicating a requirement for membrane attack components. These studies show that complement can neutralize HIV via the classical complement pathway and that this neutralization occurs via C5b-9-mediated viral lysis. Thus, complement may play a major role in resistance to disease by lysing HIV and preventing infection of Fc- and complement receptor-positive cells, as well as CD4+ cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1700828      PMCID: PMC248749     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells.

Authors:  J Homsy; M Meyer; M Tateno; S Clarkson; J A Levy
Journal:  Science       Date:  1989-06-16       Impact factor: 47.728

2.  Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release.

Authors:  W E Robinson; D C Montefiori; D H Gillespie; W M Mitchell
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

3.  Efficient isolation of HIV from plasma during different stages of HIV infection.

Authors:  A Ehrnst; A Sönnerborg; S Bergdahl; O Strannegård
Journal:  J Med Virol       Date:  1988-09       Impact factor: 2.327

4.  The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum.

Authors:  B Banapour; J Sernatinger; J A Levy
Journal:  Virology       Date:  1986-07-15       Impact factor: 3.616

5.  Enhancement of human immunodeficiency virus (HIV) replication in human monocytes by low titres of anti-HIV antibodies in vitro.

Authors:  S Matsuda; M Gidlund; F Chiodi; A Cafaro; A Nygren; B Morein; K Nilsson; E M Fenyö; H Wigzell
Journal:  Scand J Immunol       Date:  1989-10       Impact factor: 3.487

6.  Hypocomplementemia and human immunodeficiency virus infection. Clinical correlates and relationships to circulating immune complex and immunoglobulin G levels.

Authors:  R Y Lin; O Wildfeuer; M M Franklin; K Candido
Journal:  Int Arch Allergy Appl Immunol       Date:  1988

7.  Evidence for activation of complement in patients with AIDS related complex (ARC) and/or lymphoadenopathy syndrome (LAS).

Authors:  R Perricone; L Fontana; C de Carolis; C Carini; M C Sirianni; F Aiuti
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

8.  Characterization and clinical association of antibody inhibitory to HIV reverse transcriptase activity.

Authors:  J Laurence; A Saunders; J Kulkosky
Journal:  Science       Date:  1987-03-20       Impact factor: 47.728

9.  Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry.

Authors:  A Takeda; C U Tuazon; F A Ennis
Journal:  Science       Date:  1988-10-28       Impact factor: 47.728

10.  Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome.

Authors:  F A Tausk; A McCutchan; P Spechko; R D Schreiber; I Gigli
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

View more
  29 in total

1.  B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1.

Authors:  J J Jakubik; M Saifuddin; D M Takefman; G T Spear
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

2.  Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.

Authors:  Andreas Mörner; Marianne Jansson; Evelien M Bunnik; Jørgen Schøller; Robert Vaughan; Yufei Wang; David C Montefiori; Nel Otting; Ronald Bontrop; Lesley A Bergmeier; Mahavir Singh; Richard T Wyatt; Hanneke Schuitemaker; Gunnel Biberfeld; Rigmor Thorstensson; Thomas Lehner
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

3.  Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked.

Authors:  Michael Huber; Viktor von Wyl; Christoph G Ammann; Herbert Kuster; Gabriela Stiegler; Hermann Katinger; Rainer Weber; Marek Fischer; Heribert Stoiber; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

Review 4.  Survivors Remorse: antibody-mediated protection against HIV-1.

Authors:  George K Lewis; Marzena Pazgier; Anthony L DeVico
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

5.  Mechanisms of Host Resistance Against HIV Infection and Progression to AIDS.

Authors:  Ali A Al-Jabri
Journal:  Sultan Qaboos Univ Med J       Date:  2007-08

Review 6.  Complement-related proteins in pathogenic organisms.

Authors:  Z Fishelson
Journal:  Springer Semin Immunopathol       Date:  1994

7.  Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody.

Authors:  J S McDougal; M S Kennedy; S L Orloff; J K Nicholson; T J Spira
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

8.  A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays.

Authors:  Michael D Alpert; Lisa N Heyer; David E J Williams; Jackson D Harvey; Thomas Greenough; Maria Allhorn; David T Evans
Journal:  J Virol       Date:  2012-08-29       Impact factor: 5.103

9.  Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59.

Authors:  J Schmitz; J P Zimmer; B Kluxen; S Aries; M Bögel; I Gigli; H Schmitz
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

10.  Rapid clearance of simian immunodeficiency virus particles from plasma of rhesus macaques.

Authors:  L Zhang; P J Dailey; T He; A Gettie; S Bonhoeffer; A S Perelson; D D Ho
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.